Literature DB >> 21791967

Rosiglitazone protects diabetic rats from liver destruction.

Y-L Lu1, T-T Ye, Y Chen, J Yu, L-J Zhao, N-J Wang, B-R Jiang, J Qiao, L-Z Yang.   

Abstract

AIMS: To investigate whether rosiglitazone (ROS) protects diabetic rats from destructive changes in the liver.
METHODS: Twenty-four Sprague Dawley rats were randomly divided into 3 groups: control (NC) group (no.=8), streptozocin (STZ)-treated diabetic (DM) group (no.=8), and STZ+ROStreated diabetic (RSG) group (no.=8). After 8 weeks, the liver structure was observed by light microscopy and transmission electron microscopy. Apoptosis was detected by TUNEL, and apoptosis index was calculated. The Fas ligand (FasL) mRNA expression of apoptosis-promoting gene and cyclooxygenase- 2 (COX-2) mRNA in the liver were detected by RTPCR. COX-2 protein in the liver was tested via immunohistochemical staining.
RESULTS: Compared to NC group, DM group showed a visible fatty degeneration and inflammatory cell infiltration in the liver under microscopy. Obvious hepatocyte swelling with atrophic mitochondria was observed, and the central zone of cholangiole was severely outstretched. Meanwhile, in RSG group, the hepatocyte steatosis and inflammatory cell infiltration decreased, and the hepatic ultra-structure was markedly improved. Hepatocyte apoptosis (p<0.05) and the expression levels for hepatic COX-2 mRNA (p<0.05), FasL mRNA (p<0.01), and COX-2 protein (p<0.05) were higher in DM group compared to the NC group, while the expression level of hepatic COX-2 mRNA (p<0.05), FasL mRNA (p<0.01), COX-2 protein (p<0.05), and hepatocyte apoptosis (p<0.05) in RSG group were decreased compared to DM group.
CONCLUSION: Diabetes causes severe liver injury and ROS can protect diabetic rats from liver destruction, which may be related to inhibition of the expression of COX-2 and the hepatocyte apoptosis induced by FasL gene over expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791967     DOI: 10.3275/7873

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

Authors:  Erland Erdmann; Robert Spanheimer; Bernard Charbonnel
Journal:  J Diabetes       Date:  2010-09       Impact factor: 4.006

2.  Inflammation is more persistent in type 1 diabetic mice.

Authors:  D T Graves; G Naguib; H Lu; C Leone; H Hsue; E Krall
Journal:  J Dent Res       Date:  2005-04       Impact factor: 6.116

Review 3.  Phospholipase A2 inhibitors as potential anti-inflammatory agents.

Authors:  M C Meyer; P Rastogi; C S Beckett; J McHowat
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  [Hepatitis C and diabetes mellitus: effect of diabetes on the course of the liver disease].

Authors:  N Kabbaj; I Errabih; M Guédira; H El Atmani; K Benabed; Z Al Hamany; M Mohammadi; A Benaïssa
Journal:  Ann Endocrinol (Paris)       Date:  2006-06       Impact factor: 2.478

Review 5.  PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections.

Authors:  Josep Bassaganya-Riera; Rong Song; Paul C Roberts; Raquel Hontecillas
Journal:  Viral Immunol       Date:  2010-08       Impact factor: 2.257

6.  Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes.

Authors:  J Matsuda; K Hosoda; H Itoh; C Son; K Doi; I Hanaoka; G Inoue; H Nishimura; Y Yoshimasa; Y Yamori; H Odaka; K Nakao
Journal:  Diabetes       Date:  1998-11       Impact factor: 9.461

7.  Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

Authors:  Michel Komajda; John J V McMurray; Henning Beck-Nielsen; Ramon Gomis; Markolf Hanefeld; Stuart J Pocock; Paula S Curtis; Nigel P Jones; Philip D Home
Journal:  Eur Heart J       Date:  2010-01-29       Impact factor: 29.983

8.  Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes.

Authors:  Lyudmila I Rachek; Larysa V Yuzefovych; Susan P Ledoux; Neil L Julie; Glenn L Wilson
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-24       Impact factor: 4.219

Review 9.  Death receptor-induced cell killing.

Authors:  Andrew Thorburn
Journal:  Cell Signal       Date:  2004-02       Impact factor: 4.315

10.  Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma.

Authors:  Yasunori Takata; Yutaka Kitami; Zhao-Hui Yang; Michitsugu Nakamura; Takafumi Okura; Kunio Hiwada
Journal:  Circ Res       Date:  2002-09-06       Impact factor: 17.367

View more
  2 in total

1.  Effects of Chimonanthus nitens Oliv. Leaf Extract on Glycolipid Metabolism and Antioxidant Capacity in Diabetic Model Mice.

Authors:  Hui Chen; Yan Jiang; Zhanwei Yang; Wenbing Hu; Lei Xiong; Ning Wang; Xin Liu; Guodong Zheng; Kehui Ouyang; Wenjun Wang
Journal:  Oxid Med Cell Longev       Date:  2017-09-19       Impact factor: 6.543

2.  Protective Effects of Reduced Beta 2 Glycoprotein I on Liver Injury in Streptozotocin (STZ)-Diabetic Rats by Activation of AMP-Activated Protein Kinase.

Authors:  Jing-Yun Zhang; Chun-Jun Li; Qiu-Mei Zhang; Pei Yu; Jian-Ying Shi; Guang-Jie Tang; Lin-Lin Ma; De-Min Yu
Journal:  Med Sci Monit       Date:  2018-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.